8-K: Biote Corp. Settles Litigation, Repurchases Founder's Shares for $76.9 Million

Biote Corp. has reached a settlement to resolve litigation with its founder, Dr. Gary S. Donovitz, and will repurchase his shares for approximately $76.9 million.

Summary

• Biote Corp. has entered into a binding settlement term sheet to resolve litigation with its founder, Dr. Gary S. Donovitz.
• As part of the settlement, Biote will repurchase all of Donovitz's Class A shares and Paired Interests for approximately $76.9 million.
• The repurchase includes approximately 5.1 million Class A shares and 13.3 million Paired Interests.
• The average price for each repurchased share will be $4.17.
• The repurchase will occur over a three-year schedule with payments at the signing of the agreement, and at the 12, 24, and 36-month anniversaries.
• The settlement also includes a mutual release of claims, termination of the founder advisory agreement, and a two-year non-compete and non-solicitation agreement for Donovitz.

Sentiment

Score: 7

Explanation: The document is generally positive, resolving litigation and repurchasing shares, which is expected to be accretive to shareholder value. However, the cost of the repurchase and the three-year schedule temper the enthusiasm.

Positives

• The settlement resolves costly and protracted litigation.
• The share repurchase is expected to be accretive to shareholder value.
• Biote has a strong capital position and cash generation to support the repurchase.
• The company maintains its existing $20 million share repurchase authorization, separate from this agreement.

Negatives

• The company is spending $76.9 million to repurchase shares from the founder.
• The repurchase is spread over three years, which may delay the full benefit to shareholders.

Risks

• The company's success depends on the market acceptance of its dietary supplements.
• The company relies on third parties for the manufacturing of bio-identical hormones.
• The company is sensitive to regulatory, economic, environmental, and competitive conditions.
• The company faces significant competition in its industry.
• The company's ability to grow its business and expand into new markets is not guaranteed.
• The company is subject to heavy regulatory oversight.
• The company's future performance could be impacted by economic, business, and competitive factors, including recent bank failures.

Future Outlook

The company aims to advance its strategic objectives and establish itself as a leader in evidence-based therapeutic wellness. The share repurchase is expected to be accretive to shareholder value.

Management Comments

• Terry Weber, Biote Chief Executive Officer, commented, 'We are pleased to reach this agreement that not only resolves protracted and costly litigation, but also enables us to repurchase a substantial portion of our outstanding shares.'
• Terry Weber also stated, 'Supported by our strong capital position and cash generation, we are well positioned to execute this share repurchase that we believe will be accretive to shareholder value.'

Industry Context

The settlement and share repurchase are part of Biote's strategy to resolve legal issues and enhance shareholder value. This is a common practice for companies looking to streamline operations and improve investor confidence.

Comparison to Industry Standards

• Share repurchases are a common method for companies to return value to shareholders, especially when they believe their stock is undervalued.
• The average price of $4.17 per share will need to be compared to the current market price to determine if it is a good deal for the company.
• The three-year schedule for the repurchase is not unusual, as it allows the company to manage its cash flow effectively.
• The non-compete agreement is a standard practice in settlements involving founders or key personnel.

Legal Proceedings

• The company has settled its litigation with Dr. Gary S. Donovitz.

Related Party Transactions

• The share repurchase from Dr. Gary S. Donovitz is a related party transaction.

Stakeholder Impact

• Shareholders are expected to benefit from the share repurchase, which is anticipated to be accretive to shareholder value.
• The resolution of the litigation removes a potential risk for the company.
• The non-compete agreement with the founder may reduce potential future competition.

Next Steps

• The company will prepare and enter into a definitive settlement agreement.
• The company will repurchase shares from Donovitz according to the agreed schedule.
• The company will file the settlement term sheet in its next quarterly report on Form 10-Q.

Key Dates

Keywords

share repurchase, litigation settlement, founder shares, non-compete agreement, biote, BTMD, hormone optimization, therapeutic wellness